Dexcom finds stolen G7 sensors sold online

By Crystal Simmons 27/05/2026 3 min read 78 views

Dexcom has discovered two batches of its G7 continuous glucose monitoring sensors being sold to the public despite being marked for disposal. The affected lots, 1725204004 and 1725069002, were sent to a third party for destruction but were later found in circulation. The company said sensors that fail quality checks are typically discarded as part of its standard process, but this case involves theft and resale.

The issue came to light during routine reviews of inventory and accounting records. Dexcom traced the unauthorized sales back to Pharmsource, LLC, a vendor not authorized to distribute its products. Pharmacies and distributors that received goods from Pharmsource are urged to verify their stock carefully. The company is contacting U.S. customers first, as the problem primarily affects domestic users.

Users with sensors from the two lots are advised to stop using them immediately and request replacements. No serious health issues have been linked to the stolen devices, according to Dexcom. The company is cooperating with regulators to investigate how the sensors were stolen and to hold those responsible accountable.

Dexcom’s president and CEO, Jake Leach, emphasized the company’s commitment to safety and transparency. “We are treating this matter with the utmost seriousness,” he said. The incident has not affected the broader availability of the G7 system, which remains in use by millions of patients worldwide.

The discovery follows Dexcom’s recent announcement of its next-generation G8 sensor. The G8 is 50% smaller than the G7 and features improved accuracy through advanced algorithms and a new silicon chip. The device is expected to reach Medicare-covered users in the U.S. by next year, pending final approval.

The G8’s development spanned decades, according to the company, with updates focused on adapting to real-time physiological changes. Unlike the G7, the G8’s design reduces outlier readings and offers more personalized monitoring. Dexcom plans to share more details about Medicare coverage by year’s end.

While the G8 represents a technological leap, the current issue with the G7 underscores the challenges of securing medical devices. Dexcom has not disclosed how the stolen sensors were removed from its disposal chain. The company said it is working to prevent similar incidents in the future.

Pharmsource, LLC, has not publicly responded to the allegations. Independent pharmacies and durable medical equipment distributors that purchased from the vendor are being asked to audit their inventory. Dexcom’s statement does not specify how many sensors were affected or how many have been recovered.

The incident highlights the risks of counterfeit or unauthorized medical supplies entering the market. Patients relying on CGMs for diabetes management depend on the integrity of their devices. Dexcom’s response includes direct outreach to users and collaboration with law enforcement to trace the stolen goods.

As the company addresses the current crisis, it continues to push forward with the G8. The new system’s smaller size and improved performance may help expand access to CGM technology. However, the theft of G7 sensors serves as a reminder of the vulnerabilities in the supply chain for critical health devices.